Latest action: Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, the Budget, the Judiciary, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Bill aims to reduce costs for Americans on healthcare, prescription drugs, and everyday expenses.
The problem
Americans struggle with high costs for healthcare, medicines, and daily living expenses. Many people cannot afford necessary treatments or basic needs.
The proposal
The bill would address cost increases through healthcare, prescription drug, and consumer protection measures across multiple policy areas under review by several committees.
The impact
Consumers, patients, and families could see lower healthcare and drug costs. Effects on businesses, government spending, and insurance markets need committee analysis.
Reducing prescription drug prices helps patients afford needed medications. People with chronic illnesses and low-income families would benefit most. This could improve public health outcomes.
Lower healthcare costs mean families keep more money for other needs. This supports household budgets and reduces financial stress. Economic activity may increase when people spend savings elsewhere.
The bill addresses multiple cost areas including healthcare, education, and everyday expenses. This comprehensive approach recognizes many affordability challenges. It shows intent to help various populations.
Multiple committees examine the bill from different angles. This process allows thorough vetting of proposals. Different perspectives help identify potential problems early.
No official bill summary exists yet, so specific methods are unclear. Without knowing exact proposals, costs and effects cannot be assessed. This makes it hard to evaluate real impacts.
Restrictions on pharmaceutical or insurance pricing might reduce company profits. Lower revenues could slow drug development or innovation. Businesses might pass costs elsewhere.
Cost-reduction measures may require government spending or revenue changes. Budgets could increase significantly depending on the proposal. Taxpayers may face higher costs.
Multiple committees must coordinate on overlapping policy areas. Complex healthcare reform faces execution difficulties. Programs may work differently than intended.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.